Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Jul;16(6):102266.
doi: 10.1016/j.jgo.2025.102266. Epub 2025 Jun 4.

Assessing frailty in patients with relapsed/refractory multiple myeloma: A comparison between the patient-reported frailty phenotype and the International Myeloma Working Group frailty index

Daniela Krepper  1 , Francesco Sparano  2 , Johannes M Giesinger  1 , Gianluca Gaidano  3 , Pasquale Niscola  4 , Katia Codeluppi  5 , Elisabetta Antonioli  6 , Catello Califano  7 , Lajos Floro  8 , Ombretta Annibali  9 , Claudio Fozza  10 , Agostino Tafuri  11 , Patrizio Mazza  12 , Leonardo Potenza  13 , Marco Vignetti  2 , Michele Cavo  14 , Maria Teresa Petrucci  15 , Fabio Efficace  16
Affiliations
Observational Study

Assessing frailty in patients with relapsed/refractory multiple myeloma: A comparison between the patient-reported frailty phenotype and the International Myeloma Working Group frailty index

Daniela Krepper et al. J Geriatr Oncol. 2025 Jul.

Abstract

Introduction: The International Myeloma Working Group Frailty Index (IMWG FI) is one of the most used frailty assessment tools in patients with multiple myeloma (MM). A patient-centered frailty tool based on patient-reported outcomes (PROs) has been recently proposed for patients with relapsed/refractory MM (RRMM): the Patient-Reported Frailty Phenotype (PRFP). This cross-sectional analysis aimed to replicate the PRFP within a real-world setting and to describe health-related quality of life (HRQoL) profiles based on this new patient-centered frailty classification.

Materials and methods: This analysis was based on baseline data from a multi-center prospective observational study that included adult patients with RRMM. Frailty was assessed using the IMWG FI, and HRQoL was evaluated with the EORTC QLQ-C30 and its myeloma module (QLQ-MY20). For this analysis, the PRFP was also calculated, and Cohen's kappa was computed to examine the agreement between the two frailty assessment approaches. Descriptive statistics were used to investigate the HRQoL profiles of patients classified as frail, pre-frail, and fit.

Results: Five hundred eleven patients were enrolled. The median age was 69.8 years, and 44 % were female. According to IMWG FI and PRFP, 24.5 % and 25.1 % of patients were classified as frail, with a weighted Cohen's kappa of 0.27, indicating fair agreement. Frail patients, as classified by the PRFP, reported higher treatment side effects, disease symptoms, and worse future perspectives and body image compared to pre-frail and fit patients.

Discussion: Current findings suggest that the PRFP may be a valuable tool to assess frailty in patients with RRMM. However, further prospective studies are needed to better understand the value of PROs in a more accurate assessment of frailty in the RRMM setting.

Trial registration: ClinicalTrials.gov: NCT03190525.

Keywords: Frailty; Patient-reported outcomes; Relapsed/refractory multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Fabio Efficace had a consultancy or advisory role for AbbVie, Incyte, Novartis and JAZZ Pharmaceuticals and Research support (institution) from Daiichi Sankyo, all outside the submitted work. Gianluca Gaidano: Advisory Board and/or Speaker's Bureau: Abbvie, AstraZeneca, BeiGene, Hikma, Incyte, Johnson & Johnson, Lilly, all outside the submitted work. Marco Vignetti reports honoraria from AbbVie, and Novartis; all outside the submitted work. All the other authors declared no conflict of interest.

Associated data